AIMP2 and glioblastoma: Based on our findings, we propose that utilizing AIMP2 high expression as a predictive biomarker, stratified by methylation, for patient selection can potentially enhance therapeutic efficacy and improve outcomes in recurrent patients with GBM receiving antiangiogenic treatments.